Theravance settles YUPELRI patent litigation with Lupin; generic launch delayed to April 23, 2039

Theravance Biopharma, Inc.

Settlement grants Lupin a royalty-free, non-exclusive license to market generic revefenacin starting April 23, 2039.
The settlement resolves ongoing Hatch-Waxman litigation based on Lupin's ANDA for YUPELRI.
Patent litigation continues against three other ANDA filers: Cipla, Eugia Pharma, and Mankind Pharma.
Settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.